Replies to post #27915 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Correct..from the provista Diagnostics web site..If william was allowed to use DR-70 and LC Sentinel for a lung cancer test. What keeps William from using Dr-70 and LC Sentinel using the same tests for Breast Cancer? we know the reason.."Non Compete Clause" LC Sentinel was given to Provista Diagnostics and Provista Diagnostics signed an exclusive agreement with Radient for the research and expansion of DR-70..William is also an executive Vice President with provista Diagnostics..There is no way the Angel Investors and provista Diagnostics would allow William to go Rogue if that was the case..imo Wolf


Precise cancer detection
We’re committed to developing it.

Provista is developing transformational diagnostic tests
to radically change the way women's cancers are detected and managed. For the better.


http://provistadx.com/


dcspka Thursday, 03/05/15 01:49:39 PM
Re: guardiangel post# 27912
Post # of 27916

Yes, it seems women get lung cancer at a higher rate than men do nowadays in the U.S. The idea that Provista would shun this market is a classic case of disinformation.

Another reason why the LC Sentinel/Radient Pharmaceutical connection is so important to Provista.

[guardiangel]

DC in the presentation from June 2013 William stated that that ALL the studies were completed and they were having another agency geeting the test FDA approved..That was close to 2 years ago..How long does it take for FDA approval? Also William states and shows a slide that the ROC for women is 97 percent for women and 98 percent for men..It was on the GCDX for over a year at 97 percent..After we figured out that the 97 percent was the same as the LC Sentinel test, they thought it to be wiser to change it to 92 per cent..We know why that was done..We knew the TRADE SECRET...imo Wolf ahooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo

Here's Willy......Listen people...